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Background: Germ-line mutations in the DNA mismatch repair genes MLH1, MSH2, and MSH6 predispose to the
development of colorectal cancer (Lynch syndrome or hereditary nonpolyposis colorectal cancer). These mutations
include disease-causing frame-shift, nonsense, and splicing mutations as well as large genomic rearrangements.
However, a large number of mutations, including missense, silent, and intronic variants, are classified as variants of
unknown clinical significance.
Methods: Intronic MLH1, MSH2, or MSH6 variants were investigated using in silico prediction tools and mini-gene
assay to asses the effect on splicing.
Results: We describe in silico and in vitro characterization of nine intronic MLH1, MSH2, or MSH6 mutations
identified in Danish colorectal cancer patients, of which four mutations are novel. The analysis revealed aberrant
splicing of five mutations (MLH1 c.588 + 5G > A, MLH1 c.677 + 3A > T, MLH1 c.1732-2A > T, MSH2 c.1276 + 1G > T,
and MSH2 c.1662-2A > C), while four mutations had no effect on splicing compared to wild type (MLH1 c.117-34A >
T, MLH1 c.1039-8 T > A, MSH2 c.2459-18delT, and MSH6 c.3439-16C > T).
Conclusions: In conclusion, we classify five MLH1/MSH2 mutations as pathogenic, whereas four MLH1/MSH2/MSH6
mutations are classified as neutral. This study supports the notion that in silico prediction tools and mini-gene
assays are important for the classification of intronic variants, and thereby crucial for the genetic counseling of
patients and their family members.
Keywords: Colorectal cancer, HNPCC, Lynch syndrome, Mini-gene assay, Mismatch repair genes MLH1, MSH2,
and MSH6, Splicing defectBackground
Lynch syndrome, also called hereditary nonpolyposis
colorectal cancer (HNPCC), is an autosomal dominantly
inherited cancer predisposition syndrome primarily as-
sociated with germ-line mutations in the MLH1 (MIM#
120436), MSH2 (MIM# 609309), and MSH6 (MIM#
600678) genes [1]. Mutation carriers have an increased
risk of several specific cancers, in particular colorectal,
endometrial, small bowel, and ovarian cancer as well as
uroepithelial tumors. The estimated lifetime risk of* Correspondence: tvoh@rh.dk
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reproduction in any medium, provided the ordeveloping colorectal cancer with a pathogenic muta-
tion in one of these genes is up to 70% [2], depending
on the mutated mismatch repair gene and the gender of
the patient.
The MLH1, MSH2, and MSH6 proteins are involved in
the repair of single base mismatches and short insertion-
deletion loops that arise during DNA replication [3]. Muta-
tions inMLH1, MSH2, andMSH6 are scattered throughout
the genes (http://chromium.liacs.nl/LOVD2/colon_cancer/)
and include frame-shift, nonsense, missense, and splice
site mutations as well as large genomic rearrangements,
of which several have been identified in Danish Lynch
syndrome families [4-7]. However, a large number ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutations are of unknown clinical significance. It is clinic-
ally important to optimize the classification of these muta-
tions into pathogenic mutations or benign polymorphisms
in order to provide affected families with a more accurate
risk assessment but also to offer predictive (presymptomatic)
genetic testing to family members. The classification can
be facilitated by performing functional assays (reviewed by
[8]). In this study, we performed in silico analysis and
functional examinations of nine intronic MLH1, MSH2,
and MSH6 variants identified in Danish colorectal cancer
patients enabling us to classify five mutations as patho-
genic and four variants as neutral/polymorphisms.
Methods
Patients and clinical data
Following verbal and written consent blood samples were
collected from the probands (all adults) and genetic
screening was performed. Since the study is part of normal
diagnostic procedures no ethical approval was obtained
(H-4-2013-FSP-082). Clinical data regarding family pheno-
type, individual phenotype, cancer diagnosis, age at onset,
adenomas, and age at adenomas (See Additional file 1)
were obtained from the Danish HNPCC register. The
study was conducted in accordance with the Helsinki
Declaration.
MLH1, MSH2, and MSH6 screening
Genomic DNA was purified from whole blood using
Qiagen’s QIAamp DNA mini kit or Promega’s Maxwell
DNA purification system according to the accompany-
ing instructions. MLH1, MSH2, and MSH6 were ampli-
fied using intronic primer pairs flanking each exon. PCR
products were sequenced using an ABI3730 DNA analyzer
(Applied Biosystems). Moreover, genomic DNA was
examined by MLPA analysis using kit P003 and P072
(MRC-Holland). Sequence variations, except well-known
polymorphisms, were verified in a new blood sample.
MLH1, MSH2, and MSH6 variants are numbered ac-
cording to GenBank accession numbers NM_000249,
NM_000251, and NM_000179, respectively. The nomen-
clature guidelines of the Human Genome Variation
Society (www.hgvs.org/mutnomen) were used in all cases.
In silico analysis
The following five splice site prediction programs
were used to predict the effect of mutations on the ef-
ficiency of splicing: Splice Site Finder (http://www.
interactive-biosoftware.com); GeneSplicer (http://www.
cbcb.umd.edu/software/GeneSplicer); Splice Site Prediction
by Neural Network (http://www.fruitfly.org/seq_tools/splice.
html); MaxEntScan (http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq.html); and Human Splicing Finder
(http://www.umd.be/HSF/). The analysis was performedby the integrated software Alamut V.2.2.1 (http://www.
interactive-biosoftware.com). The genomic sequence span-
ning the individual mutations and nearby exons was
submitted according to the guidelines of each program
and default settings were used in all predictions. A vari-
ation of more than 10% in at least two algorithms was
considered as having an effect on splicing [9].
Mini-gene assay
Wild type exons along with at least 200 bp of 5′ and 3′
intronic sequences from MLH1, MSH2, and MSH6 were
PCR amplified from human genomic DNA using Pwo
DNA polymerase (Roche) and forward and reverse primers
carrying restriction sites for BamHI or XhoI (primer se-
quences are available on request). PCR products were
subcloned into the pSPL3 vector and all constructs were
verified by sequencing. Single nucleotide substitutions
or deletions were introduced using Finnzymes’ Phusion
site-directed mutagenesis kit or Stratagene’s QuikChange
II site-directed mutagenesis kit with PfuUltra high-fidelity
DNA polymerase according to the accompanying instruc-
tions. Wild type and mutant constructs were transfected
in duplicate into COS-7 cells as recently described [10].
Cells were harvested after 48 hours and total RNA was
extracted using NucleoSpin RNA/protein kits for total
RNA and protein isolation (Macherey-Nagel). cDNA was
synthesized using 1 μg/μl of RNA, M-MuLV reverse tran-
scriptase polymerase (New England Biolabs), and 0.5 μg/μl
of nucleotide oligo(dT)15 primer. cDNA was amplified
with Pwo DNA polymerase using the primers dUSD2 (5′-
TCTGAGTCACCTGGACAACC-3′) and dUSA4 (5′-AT
CTCAGTGGTATTTGTGAGC-3′). PCR products were
separated by electrophoresis on a 1% agarose gel containing
ethidium bromide. Each DNA band was gel purified using
GE Healthcare’s Illustra GFX PCR DNA and gel band
purification kit and sequenced with dUSD2 and dUSA4
primers.
Results
Since 1995, our department has conducted screening of
the entire coding regions and the exon-intron boundaries
of MLH1 and MSH2. Furthermore, since 2004, screening
of MSH6 and MLPA analysis of all three genes, have also
been performed. During this period, a relatively broad
spectrum of disease-causing germ-line MLH1, MSH2, and
MSH6 mutations has been identified [4-7]. However, mu-
tational screening has also identified numerous variants of
unknown clinical significance, including several intronic
variants. Five of these intronic variants were identified in
MLH1 (c.117-34A > T; c.588 + 5G >A; c.677 + 3A > T;
c.1039-8 T > A; c.1732-2A > T), three in MSH2 (c.1276 +
1G > T; c.1662-2A > C; c.2459-18delT), and one in MSH6
(c.3439-16C > T) (Table 1). The MLH1 c.117-34A > T,
MLH1 c.588 + 5G >A, MLH1 c.677 + 3A > T, MSH2
Table 1 In silico prediction of the effect of mutations on splice donor (SD) or splice acceptor (SA) sites
Gene IVS Mutation SSF (0–100) MES (0–16) NNS (0–1) GS (0–15) HSF (0–100)
MLH1 1 c.117-34A > T SA:80.80/80.80 SA:7.22/7.22 SA:0.86/0.86 SA:NI/NI SA:84.10/84.10
7 c.588 + 5G > A SD:87.56/75.41 SD:9.72/4.06 SD:0.97/NI SD:0.93/NI SD:88.47/76.30
(−13.9%) (−58.2%) (−100%) (−100%) (−13.8%)
8 c.677 + 3A > T SD:76.78/NI SD:9.22/3.55 SD:0.98/NI SD:NI/NI SD:84.99/73.21
(−100%) (−61.5%) (−100%) (−13.9%)
11 c.1039-8 T > A SA:95.48/90.38 SA:7.50/6.74 SA:0.96/0.79 SA:7.81/5.23 SA:88.87/86.88
(−5.3%) (−10.1%) (−17.7%) (−33.0%) (−2.2%)
15 c.1732-2A > T SA:86.24/NI SA:9.34/NI SA:0.99/NI SA:10.34/NI SA:84.57/NI
(−100%) (−100%) (−100%) (−100%) (−100%)
MSH2 7 c.1276 + 1G > T SD:81.67/NI SD:8.92/NI SD:0.91/NI SD:0.81/NI SD:84.70/NI
(−100%) (−100%) (−100%) (−100%) (−100%)
10 c.1662-2A > C SA:85.11/NI SA:8.01/NI SA:NI/NI SA:NI/NI SA:86.96/NI
(−100%) (−100%) (−100%)
14 c.2459-18delT SA:81.50/81.50 SA:9.97/8.33 SA:0.95/0.97 SA:5.06/4.05 SA:83.23/83.23
(−16.4%) (+2.1%) (−20.0%)
MSH6 5 c.3439-16C > T SA:85.93/85.93 SA:10.55/10.32 SA:0.95/0.96 SA:8.75/9.12 SA:89.74/89.74
(−2.2%) (+1.1%) (+4.2%)
Five prediction programs were used: Splice Site Finder (SSF), MaxEntScan (MES), NNsplice (NNS), GeneSplicer (GS), and Human Splicing Finder (HSF). The
thresholds represent score predicted for wt sequence/score predicted for mutated sequence. Scores indicate the values for SD or SA sites, respectively. Changes
relative to wild type sequences are indicated in % (bold if >10%). IVS = intron; NI = not identified.
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18delT, and MSH6 c.3439-16C > T variants were identified
in 7 independent families, whereas MLH1 c.1732-2A > T
was identified in two different families and MLH1 c.1039-
8 T >A was identified in six different families. The clinical
data from the probands are shown in Additional file 1
(excluding IHC and MSI data that was not available
from the patients). The probands belong to Amsterdam
positive families (six patients), Amsterdam-like families
(six patients), moderate risk families (two patients) or
non-HNPCC families (one patient).
The potential pathogenicity of the variants was inves-
tigated using five different in silico splice site prediction
programs which predict changes in splice site strength.
The threshold employed was a variation between the
wild type and the mutation score of more than 10% in
at least two different algorithms [9]. According to this
criterion, seven mutations, namely, MLH1 c.588 + 5G >
A, MLH1 c.677 + 3A > T, MLH1 c.1039-8 T >A, MLH1
c.1732-2A > T, MSH2 c.1276 + 1G > T, MSH2 c.1662-2A >
C, and MSH2 c.2459-18delT (Table 1) were suggested to
have an effect on splicing, whereas no splicing alterations
were predicted for the two remaining mutations (MLH1
c.117-34A > T and MSH6 c.3439-16C > T). To verify the
in silico-predicted effects, functional mini-gene experi-
ments were performed on all nine intronic variants, since
no RNA was available from the patients. Wild type and
mutant cDNA fragments including the exon of interest
and at least 200 bp of upstream and downstream intronicsequences were cloned into the pSPL3 vector and subse-
quently transfected into COS-7 cells (in duplicate). After
48 hours, mRNA was purified, analyzed by RT-PCR, and
then visualized on 1% agarose gels (Figure 1a-i). No band
size differences were observed between wild type and
mutant MLH1 c.117-34A > T (Figure 1a), MLH1 c.1039-
8 T > A (Figure 1d), MSH2 c.2459-18delT (Figure 1h),
and MSH6 c.3439-16C > T (Figure 1i). These findings
were verified by sequencing of the gel bands. In con-
trast, MLH1 c.588 + 5G > A, MLH1 c.677 + 3A > T,
MLH1 c.1732-2A > T, MSH2 c.1276 + 1G > T, and
MSH2 c.1662-2A > C mutants all revealed the presence
of alternative gel bands compared to the corresponding
wild types. The wild type MLH1 exon 7-exon 8 con-
struct generated one transcript comprising the expected
309 bp, while both MLH1 c.588 + 5G > A and MLH1
c.677 + 3A > T yielded one strong band of 266 bp and
220 bp, respectively, lacking either exon 7 or exon 8
(Figure 1b and c). Wild type MLH1 exon 16 revealed
the presence of one band at the expected size of 342 bp,
while MLH1 c.1732-2A > T resulted in one strong band
of 177 bp lacking exon 16 (Figure 1e). Wild type MSH2
exon 7 exhibited one band with the expected size of
377 bp containing exon 7, while MSH2 c.1276 + 1G > T
resulted in a 329-bp transcript lacking the last 48 bp of
exon 7 (Figure 1f). Moreover, wild typeMSH2 exon 11 re-
vealed the presence of a 275-bp transcript containing
exon 11, while MSH2 c.1662-2A > C revealed a single
band of 177 bp lacking exon 11 (Figure 1g).
(a)
300 bp
500 bp
100 bp
 268 bp = wt
MLH1 c.117-34A>T
300 bp
500 bp
 342 bp = wt
177 bp = lacking exon 16 
MLH1 c.1732-2A>T
300 bp
500 bp
100 bp
 309 bp = wt
MLH1 c.588+5G>A
300 bp
500 bp
100 bp
 548 bp = wt
MLH1 c.1039-8T>A
(b)
(e)
309 bp = wt
220 bp = lacking exon 8 
300 bp
500 bp
100 bp
MLH1 c.677+3A>T(c)
266 bp = lacking exon 7
(d)
295 bp = wt300 bp
500 bp
100 bp
MSH6 c.3439-16C>T
300 bp
500 bp
100 bp
 353 bp = wt
MSH2 c.2459-18delT
300 bp
500 bp
100 bp
 377 bp = wt
MSH2 c.1276+1G>T
300 bp
500 bp
100 bp
 275 bp = wt
MSH2 c.1662-2A>C
(f)
(g)
(h)
177 bp = lacking exon 11 
 329 bp = usage of cryptic splice site
(i)
100 bp
177 bp = lacking exon 12 
Figure 1 Mini-gene analysis of MLH1, MSH2, and MSH6 intronic mutations. COS-7 cells were transfected with wild type or mutant plasmids
in duplicate. Total RNA was isolated, and RT-PCR analysis was performed. PCR products were separated by agarose gel electrophoresis and
visualized by ethidium bromide staining. The sizes of the DNA marker (M) are indicated to the left. All PCR products were verified by sequencing.
(a) The MLH1 c.117-34A > T mutation produced a 268-bp PCR product which corresponds to wild type exon 2 (unaltered splicing). (b) The MLH1
c.588 + 5G > A mutation produced a 266-bp band corresponding to the exclusion of exon 7. (c) The MLH1 c.677 + 3A > T mutation resulted in a
220-bp band corresponding to a transcript lacking exon 8. (d) The MLH1 c.1039-8 T > A mutation produced a 548-bp PCR product which
corresponds to wild type exon 12 (unaltered splicing). (e) The MLH1 c.1732-2A > T mutation resulted in a 177-bp transcript corresponding to the
exclusion of exon 16. (f) The MSH2 c.1276 + 1G > T mutation produced a 329-bp transcript by usage of a cryptic splice donor site 48 bp within
exon 7. (g) The MSH2 c.1662-2A > C mutation resulted in a 177-bp product corresponding to a transcript lacking exon 11. (h) The MSH2 c.2459-
18delT mutation produced a 353-bp PCR product which corresponds to wild type exon 14 (unaltered splicing). (i) The MSH6 c.3439-16C > T
mutation produced a 295-bp PCR product which corresponds to wild type exon 5 (unaltered splicing).
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Mutations located in the introns of mismatch repair genes
can interfere with splicing and cause aberrant spliced
mRNA transcripts leading to non-functional mismatch
repair proteins. Several cis-acting elements, including the
donor splice site, the acceptor splice site, the branch point,
the polypyrimidine tract, and exonic/intronic splicing
enhancers and silencers, are crucial for the splicing mech-
anism. The donor splice site consists of the conserved
dinucleotides GT, whereas the acceptor splice site consists
of three regions: the conserved dinucleotides AG, the
polypyrimidine tract, and the branch point [11]. Mutations
in splicing motifs can lead to partial or complete skipping
of the neighboring exon or inclusion of intronic sequence.Moreover, a mutation can create an ectopic splice site or
activate a cryptic splice site, both of which are usually
weak and only used when a mutation disrupts the normal
splice site.
Ideally RNA from a patient should be examined by
RT-PCR analysis to establish if a mutation has an effect
on splicing. However, in many cases, RNA is not available
from the patient. Alternatively, the mutation can be exam-
ined by mini-gene analysis [12]. In fact, a high concord-
ance between RT-PCR analysis and mini-gene assay has
previously been observed [9,13-15]. As an indicative
examination prior to the mini-gene assay, several in silico
prediction tools can be used to indicate which variants
require further analysis.
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nine intronic variants identified in Danish colorectal
cancer families by in silico analysis and in vitro using a
mini-gene assay. The in silico analysis predicted altered
splicing for MLH1 c.588 + 5G > A, MLH1 c.677 + 3A > T,
MLH1 c.1039-8 T > A, MLH1 c.1732-2A > T, MSH2
c.1276 + 1G > T, MSH2 c.1662-2A > C, and MSH2
c.2459-18delT, whereas MLH1 c.117-34A > T and MSH6
c.3439-16C > T were predicted to have no effect on
splicing. It should be noted that three mutations in our
study (MLH1 c.1732-2A > T, MSH2 c.1276 + 1G > T, and
MSH2 c.1662-2A > C) are located in the highly conserved
donor and acceptor splice sites and hence they are easily
predicted by in silico programs. However, mini-gene
analysis revealed that the two mutations MLH1 c.1039-
8 T > A and MSH2 c.2459-18delT had no effect on
splicing, suggesting that the employed criterion (>10%
difference between wild type and mutant scores in at
least two programs) results in false-positive predictions
as previously shown [9].
Mini-gene analysis revealed that the MLH1 c.117-34A >
T and MLH1 c.1039-8 T > A variants had no effect on
splicing. The MLH1 c.117-34A > T variant has not been
described before, whereas our results regarding MLH1
c.1039-8 T > A confirm previous data analyzing patient
RNA [16]. Moreover, in one Amsterdam positive family
(H13), the MLH1 c.1039-8 T > A mutation was identi-
fied together with a disease-causing MLH1 mutationTable 2 The effect on splicing determined by mini-gene assay
literature
Gene IVS Mutation Frequency in the ESP database
(Eur. Am.)
Mini-gene
MLH1 1 c.117-34A > T NI No effect o
7 c.588 + 5G > A NI Out-of-fram
exon 7
8 c.677 + 3A > T NI Out-of-fram
exon 8
11 c.1039-8 T > A NI No effect o
15 c.1732-2A > T NI In-frame sk
MSH2 7 c.1276 + 1G > T NI In-frame e
of exon 7
10 c.1662-2A > C NI Out-of-fram
exon 11
14 c.2459-18delT NI No effect o
MSH6 5 c.3439-16C > T 0.43% No effect o
*The authors describe the mutation of interest, but do not examine its putative pat(c.1276C > T, p.Gln426X). In conclusion we classify
both variants as neutral (Table 2). In contrast, the
MLH1 c.588 + 5G > A and MLH1 c.677 + 3A > T muta-
tions were found to lead to exclusion of exon 7 and
exon 8, respectively. Ultimately, this leads to premature
stop codons and, therefore, both mutations are classi-
fied as disease-causing. These findings confirm previous
results showing that the MLH1 c.588 + 5G > A mutation
causes either partial skipping/deletion of exon 7 exam-
ining patient RNA [17] or skipping of exon 7 as well as
both exons 7 and 8 assesed using mini-gene assay [15],
and by results from MLH1 c.677 + 3A > C and MLH1
c.677 + 3A > G mutations showing skipping of exon 8
[18,19]. Moreover, our analysis found that MLH1 c.1732-
2A > T, which is a Danish founder mutation identified in
two Amsterdam positive families (See Additional file 1),
results in an in-frame deletion of exon 16, which contains
the PMS2 interaction domain. In the 2 families the muta-
tion co-segregates with the disease and has a lod score of
1.2 and 2.7, respectively, and in agreement with previous
reports [5,7,20] we therefore classify MLH1 c.1732-2A > T
as pathogenic. The MSH2 c.1276 + 1G > T mutation was
found to result in the activation of a cryptic splice donor
site 48 bp within exon 7, leading to an in-frame deletion
of 16 amino acids in the MSH6/MSH3 interaction do-
main. As the mutation was found to co-segregate in the
affected family with a lod score of 1.5, it is regarded as
pathogenic. This mutation has previously been describeds and an overview of the mutations listed in the
assay Described in the literature Classification
n splicing Novel Neutral
e skipping of Pagenstecher; partial deletion of
exon 7 [17]
Pathogenic
Tournier; deletion of exon 7 and
exons 7–8 [15]
e skipping of Novel Pathogenic
n splicing Betz; No effect on splicing [16] Neutral
ipping of exon 16 Jäger* [5] Pathogenic
Nilbert* [7]
Wijnen* [20]
xclusion of 48 bp Mangold* [21] Pathogenic
e skipping of Novel Pathogenic
n splicing Novel Neutral
n splicing Perez-Cabornero* [22] Neutral
Pinto* [23]
Sanchez de Abajo* [24]
hogenic effect. IVS = intron; NI = not identified.
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immunohistochemical analysis of these tumors revealing
the absence of nucleic MSH2 expression [21]. Similar re-
sults and conclusions have been reported for the MSH2
c.1276 + 1G >A mutation [16]. The MSH2 c.1662-2A > C
mutation has not previously been described. We found
that this mutation leads to skipping of exon 11 and conse-
quently introduce a premature stop codon. Therefore, this
mutation is classified as pathogenic. Finally, the MSH2
c.2459-18delT and MSH6 c.3439-16C > T variants were
found to have no effect on splicing and are, therefore,
classified as neutral. The MSH2 c.2459-18delT variant
has not been described before, whereas the MSH6
c.3439-16C > T variant has previously been shown not
to co-segregate with the disease and to be observed in
healthy control individuals [22-24] and in the exome
sequencing project (ESP) database (0.43%), thereby
supporting the notion that this variant is neutral.
Overall, in all Amsterdam positive families - except
one (H229) - a pathogenic mutation was identified. The
index individual in family H229 had rectum cancer at
age 58 and transverse colon cancer at age 66. His sister
and two maternal cousins all had adenomas, while his
mother has caecum cancer at age 48. Moreover his
maternal aunt had transverse colon cancer at age 69 and
his maternal grandmother had ascending colon cancer.
The lack of a pathogenic mutation in this family could be
due to an unidentified mutation in regions not previously
examined, including the promoter region, the untranslated
regions (UTRs) or deep intron sequences in the MLH1,
MSH2 or MSH6 genes, or due to a mutation in other
genes like PMS2. Future studies using exome sequencing
might help identifying a putative pathogenic mutation in
this family.Conclusion
In conclusion, we have examined nine MLH1/MSH2/
MSH6 intronic mutations by in silico and functional as-
says, thus enabling us to classify five mutations as patho-
genic and four variants as neutral/polymorphisms. This
study supports the notion that in silico prediction tools
and mini-gene assays are important for the assessment
of the pathogenicity of intronic variants, together with
clinical data, IHC and MSI.Additional file
Additional file 1: Clinical data from individuals with MLH1, MSH2,
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